Key result
In real-time analysis for acute ischemic coronary syndrome, the Beckman Access assay yielded significantly lower specificities (18% and 11%) compared to the Bayer ACS:180 (87%) and Abbott AxSYM (78%) assays.
Why the study?
Do different cardiac troponin-I immunoassays performed in real-time accurately correlate with the diagnosis of acute ischemic coronary syndrome in adult telemetry patients?
Observational (n=194)
Single-blind
No
Do different cardiac troponin-I immunoassays performed in real-time accurately correlate with the diagnosis of acute ischemic coronary syndrome in adult telemetry patients?
Absolute Event Rate: 18% vs 87%
In real-time clinical analysis, the Abbott AxSYM and Bayer ACS:180 assay systems produced more accurate troponin-I results with significantly fewer false positives than the Beckman ACCESS system.
No takes yet. Share an insight, caveat, or question.
May increase false-positive troponin results with Beckman Access; challenges assay interchangeability and leaves open standardized validation.
Baevsky et al. (2004) conducted an observational in Acute ischemic coronary syndrome (n=194). Beckman Access cardiac Troponin-I assay vs. Bayer ACS:180 and Abbott AxSYM assays was evaluated on Specificity for detecting acute ischemic coronary syndrome (Arm-1). In real-time analysis for acute ischemic coronary syndrome, the Beckman Access assay yielded significantly lower specificities (18% and 11%) compared to the Bayer ACS:180 (87%) and Abbott AxSYM (78%) assays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: